April 27, 2017
BASF profit €322M up in Q1 2017
BASF, a Germany based chemical company has reported results for Q1 2017.
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
April 26, 2017
FDA warns 14 USA companies selling fake treatments for cancer
The U.S. Food and Drug Administration today posted warning letters addressed to 14 U.S.-based companies illegally selling more than 65 products that fraudulently claim to prevent, diagnose, treat or cure cancer.
April 26, 2017
ANDA approvals time reduction can reduce drug costs
Girish Malhotra, President of EPCOT International, and CPhI Worldwide Annual Industry Report member, discusses the necessity of time reduction for ANDA approvals, arguing that if the current approval time can be reduced from ten months to three months, drug costs will decrease.
April 26, 2017
J&J, Takeda among interested in Brazil’s Hypermarcas, sources say
Johnson & Johnson <JNJ.N>, Novartis AG <NOVN.S> and Takeda Pharmaceutical Co Ltd <4502.T> have expressed interest in a buyout of the controlling stake that two families have in Brazilian drugmaker Hypermarcas SA <HYPE3.SA>, two people with knowledge of the matter said on Monday
April 25, 2017
Servier, CTI BioPharma expand Pixuvri deal
Servier and CTI BioPharma Corp. will expand their agreement regarding Pixuvri, which will give Servier rights to sell it anywhere but…
April 25, 2017
Orexigen closer to weight loss product deal in canada
Orexigen Therapeutics said that Health Canada has accepted to review a New Drug Submission for marketing approval of its products Contrave (naltrexone HCl and bupropion HCl).
April 25, 2017
Ferring Pharmaceuticals launches two products for women with infertility
Ferring Pharmaceuticals has launched two new resources to help women struggling with infertility. The products were launched during the National Infertility Awarenes Week.
April 25, 2017
Amgen, Novartis expand mutual work on migraine
Amgen and Novartis have formed a coalition that will be expanded and, as they hope, bring easier launching of a migraine related product, the USA-based company said late Monday.
April 25, 2017
Bristol-Myers and Transgene testing combination of their cancer drugs
Bristol-Myers Squibb and Transgene have entered a new clinical research collaboration to evaluate the safety, tolerability and efficacy of Transgene’s investigational therapeutic vaccine TG4010 in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) + standard chemotherapy (CT) as a first-line treatment for advanced non-squamous non-small cell lung cancer (NSCLC) in patients whose tumors have low or undetectable levels of PD-L1.
April 25, 2017
Generic competition offsets Novartis’s 1Q sales, net income 15% down
Novartis’ has posted a first quarter net income down 15% citing a net charge related to the discontinuation of RLX030 ($-0.2 billion), as well as the decline in core operating income.